Proton pump inhibitors – lansoprazole
Last updated on March 19, 2025
Return to Special Authority drug list
Generic name |
lansoprazole |
|
|---|---|---|
Strength & form |
15 mg, 30 mg capsule and rapid-dissolve tablet |
|
Special Authority criteria |
Approval period |
|---|---|
|
For gastroesophageal reflux disease (GERD), reflux esophagitis, duodenal ulcer, or gastric ulcer |
Indefinite |
|
For Barrett's esophagus, Zollinger-Ellison syndrome, connective tissue disease, e.g., lupus, scleroderma, CREST |
Indefinite |
|
For eradication of Helicobacter pylori, as part of triple therapy |
14 days |
|
PLUS Failure of reasonable trials of, or intolerance to, rabeprazole AND pantoprazole magnesium |
Practitioner exemptions
- No practitioner exemptions
Special notes
-
CREST is an acronym for the five main features of the limited form of scleroderma: Calcinosis, Raynaud’s disease, esophageal dysmotility, sclerodactyly, and telangiectasia
-
A reasonable trial of rabeprazole and pantoprazole magnesium is considered a trial at usual adult doses for at least 4 weeks each of rabeprazole and pantoprazole magnesium